












































Inflammation is a response of vascularised tissue to sub-
lethal injury [1]. Inflammation can be classified according
to duration as either acute or chronic. In acute inflamma-
tion, changes in small blood vessels result in fluid and
granulocytic cells accumulating at the site of injury. This
reaction may trigger a systemic response such as fever,
leucocytosis, protein catabolism, and altered hepatic syn-
thesis of plasma proteins such as C-reactive protein.
Chronic inflammation is characterised by tissue infiltration
by macrophages and lymphocytes.
Inflammation may be considered a homeostatic response
designed to destroy or inactivate invading pathogens,
remove waste and debris, and permit restoration of normal
function, either through resolution or repair. Tissue struc-
ture is normal after resolution, whereas repair leads to a
functional, but morphologically altered, organ. In acute
inflammation, tissue damage is followed by resolution,
whereas in chronic inflammation, damage and repair con-
tinue concurrently. The initial inflammatory response is
usually acute, and may or may not evolve into chronic
inflammation. However, chronic inflammation is not always
preceded by an acute phase. Although usually beneficial
to the organism, inflammation itself may lead to tissue
damage, resulting in escalation of chronic inflammation.
Angiogenesis
Angiogenesis is the growth of new capillary blood vessels
from pre-existing vasculature [2]. It is a fundamental
process required for embryogenesis, growth, tissue repair
after injury, and the female reproductive cycle. It may also
contribute to the pathology of conditions such as cancer,
psoriasis, diabetic retinopathy, and chronic inflammatory
diseases in joints or lungs. Angiogenesis is stimulated
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when hypoxic, diseased, or injured tissues produce and
release angiogenic promoters such as vascular endothelial
growth factor (VEGF) or fibroblast growth factor (FGF)-1.
These angiogenic factors stimulate the migration and pro-
liferation of endothelial cells in existing vessels and, subse-
quently, the formation of capillary tubes and the
recruitment of other cell types to generate and stabilise
new blood vessels.
Inflammation may promote angiogenesis in a number of
ways [3–5]. Inflammatory tissue is often hypoxic, and
hypoxia can induce angiogenesis through upregulation of
factors such as VEGF. Extravasated plasma proteins such
as fibrinogen products may stimulate neovascularisation.
Inflammatory cells such as macrophages, lymphocytes,
mast cells, and fibroblasts, and the angiogenic factors
they produce, can stimulate vessel growth. Many
proinflammatory cytokines, such as tumour necrosis
factor(TNF)-a, may have angiogenic activity in addition to
proinflammatory activity. Increased blood flow itself may
stimulate angiogenesis through shear stresses on the
endothelium. Inflammation also may upregulate the expres-
sion of angiogenic growth factors such as VEGF and
FGF-1 by resident cells such as fibroblasts [6,7].
Inflammation in the joint
The synovial joint has a specialised structure allowing both
stability and movement. The normal synovial lining is highly
vascular, providing support to the avascular articular carti-
lage (Fig. 1a) [8]. The synovial vasculature is fed by a variety
of arteries, which anastomose and branch in arcades
towards the synovial lining region. The deeper layers of the
articular cartilage also may obtain metabolic support from
blood vessels at the osteochondral junction. Vascular prolif-
eration is not usually a feature of the normal joint [7].
Trauma and disease are both causes of joint inflamma-
tion. Joint swelling due to inflammation may be caused by
intra-articular effusion, synovial thickening, periarticular
soft-tissue inflammation (bursitis or tendonitis), and even-
tually bony enlargement. Injury may lead to chronic condi-
tions in some instances, such as osteoarthritis induced by
trauma, although the initiating factor is unknown in most
forms of arthritis. The diseases in which synovial inflam-
mation is common include rheumatoid arthritis and
osteoarthritis, seronegative spondylarthropathies, and
septic arthritis.
During joint inflammation, increased angiogenesis leads to
reorganisation of articular blood vessels [9,10]. There are
reduced vascular densities adjacent to the synovial lining
region, increased vascular densities in the deeper syn-
ovium, growth and invasion of vascularised pannus into
articular cartilage and subchondral bone, and vascularisa-
tion and endochondral ossification at the osteochondral
junction (Fig. 1b).
Inflammatory conditions in the lung
The lung is a highly specialised and vital organ, which has
evolved to maximise gas exchange. It possesses a dual
circulation. The bronchial, systemic circulation provides for
the metabolic requirements of the lung tissues. The pul-
monary circulation transmits deoxygenated blood through
the interface with the alveolar airspace. Each circulation is
highly organised and tightly regulated in the normal lung,
with few anastomoses between the two.
Each compartment of the lung may be affected by
chronic inflammation, with functional consequences that
Figure 1
Vascular plasticity in rheumatoid arthritis and osteoarthritis. (a) Vascular
distribution in the normal joint. Blood vessels in the synovium (s) are highly
organised, with larger vessels sparsely distributed in the sublining region,
branching to form dense microvascular networks adjacent to the synovial
surface and capsule (cap). An additional vascular network in the
subchondral bone (b) does not normally cross into the articular cartilage
(cart), which remains avascular. (b) In rheumatoid arthritis (RA),
hyperplastic synovial pannus (p) attaches to and invades articular
cartilage and adjacent bone. The synovial vascular network is reorganised,
leading to reduced vascular densities adjacent to the joint space and
increased vascular densities in the deeper synovium. Similar changes in
vascular organisation occur in the synovium in osteoarthritis (OA).
However, rather than destruction of bone and cartilage by pannus,
vascular invasion of cartilage in the developing osteophyte (o) and at the
osteochondral junction may lead to advancing endochondral ossification.
Innervation of new vessels by fine, unmyelinated sensory nerves may









































reflect the role of that structure. Mural inflammation in
muscular airways contributes to limitation of airflow,
which may be variable (asthma) or fixed. Intraluminal
inflammation is a feature of bronchiectasis and bronchi-
olitis obliterans organising pneumonia (BOOP). Inflam-
mation of the lung parenchyma may lead to thickening of
the alveolar septa or filling of alveolar spaces with granu-
lation tissue and subsequent fibrosis. This pulmonary
fibrosis may be a result of a variety of lung injuries,
including neonatal hyperoxia, adult respiratory distress
syndrome, infection, or extrinsic allergic alveolitides. Pul-
monary fibrosis is often idiopathic, as in interstitial organ-
ising pneumonia or idiopathic pulmonary fibrosis. Pleural
inflammation may result from infection or be idiopathic.
Inflammation of the large airways may be a particular
challenge in lung transplantation. Finally, unlike the joint,
the lung is a common site for primary and secondary
neoplasia, the inflammatory response to which may
modify clinical features.
Inflammatory lung disease is not uncommon in rheumatic
conditions [11,12]. Patients with rheumatoid arthritis have
an increased susceptibility to chronic suppurative lung
disease and BOOP. Pulmonary fibrosis and pleural inflam-
mation may be specific features of a variety of rheumato-
logical conditions, including rheumatoid arthritis, systemic
lupus erythematosus, and systemic sclerosis.
The extent to which these disease associations reflect
common pathological mechanisms or linked genetic or
environmental susceptibility remains unknown. At present
it seems unlikely that primary abnormalities of vascular
growth will explain the incidence and association of pul-
monary and articular inflammation. However, both syn-
ovium and lung have evolved as highly vascular tissues.
Vascular turnover is extremely low in normal synovium and
lung. Synovial and lung microvasculatures are finely organ-
ised, with highly developed neurovascular regulatory
systems. Destabilising their microvasculatures through
angiogenesis may have consequences that are shared
between the two organs.
Methods
This review is directed at hypotheses rather than observa-
tions. In any area of research, the original ideas are the ini-
tiating events, and from these, experiments are designed
and observations collected. This review addresses
hypotheses about the role of angiogenesis in the patho-
genesis of inflammatory disease. Hypotheses from two
separate areas have been compared, the joint and the
lung. The mechanisms by which inflammation may cause
angiogenesis are not addressed in detail, as these have
been extensively reviewed elsewhere [2,3,13,14]. Simi-
larly, readers are referred to the referenced articles and
reviews for more detailed discussions of the quality of evi-
dence supporting the identified hypotheses.
Articles were identified using the MEDLINE database 1966
to July 2000, and references cited within these articles.
Search terms for lung or joint diseases were combined with
terms for angiogenesis. One hundred and forty abstracts
relating to lungs and 126 relating to joints were identified,
leading to detailed review of 49 and 41 articles respectively.
Reviewed hypotheses
Potentiation of inflammation by angiogenesis
It is commonly hypothesised with regard to both lungs and
joints that angiogenesis potentiates inflammation. Angio-
genic factors are often proinflammatory; expression of
adhesion molecules such as integrin avb3 and e-selectin is
upregulated in the neovasculature, and new vessels
appear particularly sensitive to inflammogens [15–19].
The angiogenic factor FGF-1 enhances antigen-induced
synovitis in rabbits but is not proinflammatory when admin-
istered alone [20]. Hypotheses that angiogenesis potenti-
ates inflammation are supported by the observation that
synovitis in laboratory animals is inhibited by agents that
inhibit angiogenesis, such as TNP470, integrin av antago-
nists, 2-methoxyestradiol, paclitaxel, and P38 mitogen-
activated protein kinase inhibitors [20–25]. However,
angiogenesis can occur in the absence of inflammation,
for example during embryonic growth and in the female
reproductive cycle. Furthermore, all agents so far reported
may have anti-inflammatory activity independent of their
anti-angiogenic activity. Inflammation and angiogenesis
can occur independently, although it seems likely that their
coexistence may lead to more severe, damaging, and per-
sistent inflammation [26].
Tissue growth
A role for angiogenesis in enhancing tumour growth is now
widely accepted, and a variety of anti-angiogenic agents
are in clinical development. Folkman championed the
concept that vascular growth permits tumour growth, and
that tumours cannot grow beyond a few millimetres in
diameter in the absence of angiogenesis [27]. Mechanisms
for angiogenesis-dependent tumour growth were originally
conceived in terms of the neovasculature meeting the
metabolic requirements of the expanding tissue. Extensions
to the hypothesis have proposed other mechanisms,
including generation of growth factors by vascular cells
and inhibition of apoptosis in the growing tissue [28,29].
Preventing the function of growth factors such as VEGF
can abolish pathological angiogenesis in tumours.
Angiogenesis may contribute to thickening of airways in
asthma and of lung parenchyma in pulmonary fibrosis, and
to growth of sarcoid granulomas [30–33]. Growth of gran-
ulation tissue into airspaces also may be angiogenesis-
dependent in bronchi after lung transplantation, in
bronchioles in BOOP, and in alveoli after acute lung injury
or in other forms of pulmonary fibrosis [34]. In each of
these situations, the expanded tissue may impair function.
Available online http://arthritis-research.com/content/3/3/147Subepithelial thickening of the airway wall results in
reduced luminal diameter that is exacerbated by bron-
choconstriction [35]. Obstruction of airways or replace-
ment of alveolar airspaces by granulation tissue impairs
circulation of gases and gas exchange. Pathophysiological
enhancement of the tissue’s normal function may lead to
increased bronchial responsiveness to exercise and aller-
gens [36,37].
Angiogenesis may also contribute to growth of the syn-
ovial pannus in rheumatoid arthritis [20,24,38–42]. Mass
effects of increased synovial volume have rarely been con-
sidered in detail. Although synovial swelling is clinically
apparent, obstructive effects on movement of synovial
fluid or the joint itself may not be of great importance.
Interposition of expanded, innervated synovium between
articulating surfaces may contribute to pain on movement.
Rheumatologists have focused more on pathophysiologi-
cal than mechanical consequences of tissue growth.
Enhancement of the tissue’s normal function may con-
tribute to excessive formation of synovial fluid. The
expanded synovium, furthermore, is recognised as an
abnormal tissue that has acquired novel activities such as
antibody and cytokine production, adhesion, and invasion
of articular cartilage and bone [43].
Inhibitors of angiogenesis can reduce tumour bulk, by shift-
ing the balance from tumour cell proliferation to apoptosis
[29]. Increased cell turnover is also a feature of inflamma-
tory diseases in both joints and lung, raising the possibility
that inhibiting angiogenesis may reduce tissue mass in
those organs also [7,40,44]. Clinical benefit from debulk-
ing synovium has already been indicated through surgical
and radiation synovectomy. Inhibition of angiogenesis may
permit repeated polyarticular medical synovectomy.
Vascular reorganisation
Normal lung and synovium both have highly organised and
regulated microvascular beds. Increased vascular turnover
leads to reorganisation of the microvasculature and to
changes in vasoregulatory systems, characterised by
reduced innervation and increased sensitivity to inflamma-
tory mediators [4].
In pulmonary fibrosis, vascular redistribution may result in
reduced vascular densities in alveolar walls adjacent to
the airspace, with increased numbers of vessel profiles
located further from the airspaces than the diffusion dis-
tance for oxygen. Capacity for vascular proliferation may
be greater in bronchial vessels than in pulmonary vessels,
leading to a greater contribution of systemic blood flow to
lung perfusion [45,46].
The numbers of bronchopulmonary anastomoses are
increased in a wide variety of inflammatory lung diseases,
including after acute lung injury and in pulmonary fibrosis,
bronchiectasis, and lung abscess [46–48]. Obliteration of
airspaces, vascular redistribution, and bronchopulmonary
anastomoses combine to impair gas transfer. Together
they produce physiological shunting of blood from
bronchial to pulmonary circulations, retrograde blood flow
within the pulmonary vessels, increased pulmonary artery
pressure and oxygen tension, and an increase in bronchial
blood flow from the normal 1% to as much as 35% of
cardiac output [33,48]. New blood vessels respond with
increased plasma extravasation to proinflammatory agents
such as substance P, and the resulting tissue oedema
may further contribute to increased tissue mass and
damage [37,49,50].
Synovial angiogenesis also leads to vascular reorganisa-
tion. Chronic synovitis is associated with vascular rarefac-
tion adjacent to the synovial surface and increased
vascular densities further away from the joint space [9,10].
The microvasculature of chronic synovitis resembles that of
other neovascular beds with reduced innervation and
increased plasma extravasation [7,51]. The role of shunting
in the inflamed synovium, however, has received little atten-
tion. Structures resembling arteriovenous anastomoses
have been described in normal synovium, and during syn-
ovitis, reduction of temperature gradients from the synovial
cavity (normally warmer) to the skin suggests that diversion
of the flow of oxygenated blood away from the synovial
surface may be a feature of inflammatory synovitis [8].
Changes in the distribution of blood flow may contribute
to synovial hypoxia and to the maintenance of synovial
inflammation and impaired cartilage metabolism [7,9,52].
Indeed, neovascularisation may generate an immature, dis-
regulated microvascular bed with a reduced capacity to
match perfusion to local metabolic demand [40]. Inhibition
of angiogenesis in the early stages of inflammation may
retain organisation and maturity of the microvasculature to
enable resolution with matching of vascular function to
tissue requirements. Identification of factors that facilitate
regression of aberrant vessels or promote the develop-
ment of vasoregulatory systems may be helpful where vas-
cular reorganisation has already occurred.
Tissue phenotype
As well as permitting tissue growth, neovascularisation
can alter tissue phenotype. Angiogenesis in tumours has
been associated with a phenotypic switch associated
with rapid growth and metastasis. This angiogenic switch
may precede oncogenic transformation, with increased
vascular densities associated with ‘preneoplastic’, dys-
plastic bronchial epithelium [28]. Osteoblastic transfor-
mation and ossification follow vascular invasion of
cartilage [53,54]. Inhibition of angiogenesis can prevent
endochondral ossification and may have potential thera-
peutic application in inhibiting new bone formation in
Arthritis Research    Vol 3 No 3 Walsh and Pearsonosteoarthritis and spondylarthropathies. Further research
may identify specific, vascular-derived factors that facili-
tate phenotypic changes from cartilage to bone, or from
dysplastic to neoplastic epithelium.
Tissue repair
Much attention has focused on potentially damaging con-
sequences of angiogenesis, although another school of
thought emphasises the essential role of angiogenesis in
tissue repair. Bronchial dehiscence remains an important
complication of lung transplantation and appears related
to ischaemia in the transplanted tissue [34,48,55].
Enhancement of neovascularisation has been considered
to minimise the risk of dehiscence, using, for example, vas-
cularised omental grafts or angiogenic growth factors
[34,48,55].
A reparative role of angiogenesis has also been proposed
in nontraumatic inflammation. Greater luminal angiogene-
sis in BOOP than in idiopathic pulmonary fibrosis has
been proposed as an explanation for the better prognosis
of BOOP and its greater responsiveness to therapy [45].
We similarly proposed that angiogenesis in the very early
phase of synovitis might help to maintain joint nutrition and
facilitate resolution or repair [40]. In an animal model of
synovitis, however, angiogenesis at day 3 predicted per-
sistence rather than the resolution of inflammation, leading
us to prefer an alternative hypothesis that disruption of the
normal synovial vasculature impairs recovery from acute
inflammatory synovitis [40].
The outcome of chronic inflammation can be viewed as a
balance between inflammation/injury and repair. The
effects of angiogenesis inhibition on this balance will
require careful study in each clinical situation.
Haemorrhage
New vessels have incomplete walls and may be particu-
larly susceptible to disruption and extravasation of blood.
This has been proposed as a cause of haemoptysis and
pulmonary haemorrhage in inflammatory lung disease
[5,48,56]. Haemosiderin deposition and extravasated red
cells are commonly observed in inflammatory synovitis,
although the contribution of angiogenesis to synovial
microhaemorrhage is unknown, and its contribution to syn-
ovial inflammation remains unclear. The inflammatory
potential and algesic effect of haemarthrosis is evident,
however, in patients with haemophilia.
Angiogenesis, the innocent bystander
Although rarely expounded in print, an alternative hypothe-
sis should be considered: that angiogenesis plays no part
in the pathogenesis or clinical consequences of chronic
inflammation. Angiogenesis has been described as a ‘side
effect’ of granuloma formation, or a ‘bystander’ to growth
factors in asthma [48,57]. However, evidence that angio-
genesis is important in chronic inflammation is no weaker
than was that for the pivotal role for TNF-a at the begin-
ning of development of anti-TNF therapies. More evidence
should be sought before the more exciting hypotheses
can be rejected.
Conclusions
Angiogenesis and inflammation are codependent processes
[58]. Some forms of inflammation, especially chronic inflam-
mation, can stimulate vessel growth. New vessels may con-
tribute to a tissue’s altered inflammatory response.
Angiogenesis and inflammation, however, remain distinct
processes that can occur independently of each other. Inhi-
bition of chronic inflammation may be expected to inhibit
angiogenesis where the stimulus for vascular growth is
derived from inflammatory cells such as macrophages [20].
Some anti-inflammatory agents may also have anti-angio-
genic activity that is independent of their effects on inflam-
mation [58–62]. Evidence is now accumulating that agents
that have been designed to specifically inhibit angiogenesis
may also inhibit chronic inflammation [20,24,25].
Perhaps the most important application of angiogenesis
inhibitors in inflammation will be in preventing the clinico-
pathological consequences of vascular growth. Angiogen-
esis inhibitors may be able to inhibit tissue growth and
remodelling, impair the formation of vascular anastomoses,
shunting, and mismatch between blood flow and meta-
bolic demand, and normalise vascular reactivity. Other
proposed therapeutic applications in arthritis have
included reducing joint damage, preventing the develop-
ment or persistence of synovitis, and reducing inflamma-
tion and pannus growth.
In this review we have focused on hypotheses, rather
than the evidence that supports or refutes those hypothe-
ses. It was not possible to identify the origins or author-
ship of most hypotheses in published articles. Despite
this limitation, the current review draws attention to the
intellectual background that has led the researchers cited
to investigate diverse potential consequences of angio-
genesis in inflammation.
Reviewing the possible roles of angiogenesis in inflamma-
tory lung disease suggests additional possible mechanisms
by which angiogenesis may contribute to human joint dis-
eases. Does fragility of new vessels within the synovium
lead to recurrent microhaemorrages that sustain inflamma-
tion? Does the growing vasculature generate factors that
transform the surrounding tissue? Do these factors increase
proliferation or endochondral ossification, and do they
increase invasiveness in the rheumatoid pannus, or increase
synovial fibrosis? Does angiogenesis generate vascular
anastomoses within the synovium, with shunting of blood
away from the synovial surface, impairment of cartilage








































hGeneral reduction of vessel growth by nonselective angio-
genesis inhibitors may have limited therapeutic application
in chronic diseases such as rheumatoid arthritis because
of predictable adverse effects of inhibiting physiological
and reparative angiogenesis [4]. The nature and regulation
of angiogenesis may differ in different physiological and
pathological states. Refining hypotheses about the spe-
cific aspects of angiogenesis that it would be desirable to
inhibit in inflammation should lead to the development of
more specific and less toxic pharmacological agents that
can complement other therapeutic strategies in human
arthritis and lung disease.
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